Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Cutaneous T-cell lymphomas (CTCL) are rare, skin-predominant non-Hodgkin lymphomas characterized by malignant T-cell infiltration of the skin, with mycosis fungoides representing the most common subtype. As reported by recent European epidemiological evidence (2025), CTCL has an incidence of approximately 0.3 cases per 100,000 patient-years across Europe. According to the cutaneous T-cell lymphoma pipeline analysis by Expert Market Research, the therapeutic pipeline is steadily expanding, driven by persistent unmet clinical needs and advances in immunology and targeted drug development. Emerging treatment approaches include monoclonal antibodies, antibody–drug conjugates, immune modulators, and novel targeted therapies.
-
Major companies involved in cutaneous T cell lymphoma pipeline analysis include Soligenix, Domain Therapeutics SA, Boston Immune Technologies and Therapeutics, and others.
-
Leading drugs currently in the pipeline include Hypericin, BITR2101, DT-7012, and others.
-
The cutaneous T-cell lymphoma is primarily driven by high unmet treatment need in relapsed and refractory patients, increasing disease awareness, and the advancement of targeted and immunotherapy-based treatment options.
Report Coverage
The Cutaneous T-cell Lymphoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into cutaneous T-cell lymphoma (CTCL) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cutaneous T-cell lymphoma (CTCL). The cutaneous T-cell lymphoma (CTCL) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The cutaneous T-cell lymphoma (CTCL) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with cutaneous T-cell lymphoma (CTCL) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cutaneous T-cell lymphoma (CTCL).
Read more about this report - Request a Free Sample
Cutaneous T-cell Lymphoma (CTCL) Pipeline Outlook
CTCL is a rare non-Hodgkin lymphoma caused by malignant T-cell proliferation leading to skin-homing lymphocyte infiltration, cytokine dysregulation, and tumor microenvironment immune escape. Disease progression is associated with chronic inflammation, immune evasion pathways, and genetic mutations affecting T-cell signaling. Current treatment strategies include skin-directed therapy, systemic immunotherapy, immune checkpoint inhibitors, targeted biologics, and emerging cell-based therapies, aiming to improve lesion clearance, reduce pruritus, and enhance survival outcomes. Denileukin diftitox-cxdl (Lymphir) is a recombinant fusion protein targeting interleukin-2 receptors on malignant T-cells, approved by the FDA in August 2024 for relapsed or refractory Cutaneous T-cell Lymphoma. It demonstrated a 36.2% objective response rate in Phase 3 trials, offering a novel targeted systemic treatment option.
Cutaneous T-cell Lymphoma (CTCL) Epidemiology
According to Soligenix, cutaneous T-cell lymphoma (CTCL) is a rare subset of non-hodgkin lymphoma, accounting for nearly 4% of over 1.7 million cases in the United States and Europe. It affects approximately 31,000 individuals in the United States with nearly 3,200 new cases annually, and around 38,000 individuals in Europe with about 3,800 new cases annually, based on SEER and ECIS data. As per Chalid Assaf et al., 2023, incidence ranged from 3.65 to 3.92 per 100,000, with a six-year prevalence of 27.35–43.58 per 100,000. The patient population was predominantly male, highlighting a steady disease burden.
Cutaneous T-cell Lymphoma (CTCL) – Pipeline Therapeutic Assessment
This section of the report covers the analysis of cutaneous T cell lymphoma drug candidates based on several segmentations including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The cutaneous T cell lymphoma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Cutaneous T-cell Lymphoma (CTCL) Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 47%, covers a major share of the total cutaneous T cell lymphoma clinical trials. It is followed by phase I at 46% and phase III at 4%. This strong mid-stage concentration indicates robust clinical progression, supporting accelerated development, improved therapeutic options, and positive market expansion through innovation and late-stage validation.
Cutaneous T-cell Lymphoma (CTCL) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the cutaneous T cell lymphoma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The cutaneous T cell lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cutaneous T cell lymphoma. Targeted therapies, including monoclonal antibodies and kinase inhibitors, are emerging as key drug class segments. For instance, lacutamab, a first-in-class anti-KIR3DL2 monoclonal antibody, is being evaluated in Phase 3 TELLOMAK 3 trials for Sézary syndrome and mycosis fungoides. Moreover, novel biologics aims to improve response rates and address high unmet clinical needs in relapsed and refractory cutaneous T-cell lymphoma patients.
Cutaneous T-cell Lymphoma (CTCL) Clinical Trials – Key Players
The EMR report for the cutaneous T cell lymphoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cutaneous T cell lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cutaneous T cell lymphoma clinical trials:
- Soligenix
- Domain Therapeutics SA
- Boston Immune Technologies and Therapeutics
- Legend Biotech USA Inc.
- SciTech Development, Inc.
- Jiangsu Simcere Biologics Co., Ltd
- Kyowa Kirin, Inc.
- Treeline Biosciences, Inc.
- Bio-Path Holdings, Inc.
- Daiichi Sankyo Co., Ltd.
- Seagen Inc.
- Bristol Myers Squibb Company
Cutaneous T-cell Lymphoma (CTCL) – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for cutaneous T cell lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of cutaneous T cell lymphoma drug candidates.
Drug: Hypericin
HyBryte™ (Hypericin Sodium Gel) is a topical photosensitizing drug being administered by Soligenix in a Phase 3 confirmatory study for cutaneous T-cell lymphoma (CTCL). The study examines whether twice-weekly application of 0.25% hypericin gel, followed by visible-light activation, induces lesion reduction in patch/plaque mycosis fungoides patients. The drug functions as a photoactive agent generating cytotoxic reactive oxygen species upon light exposure, targeting malignant T-cells locally. The trial is being sponsored by Soligenix and is evaluating efficacy and safety over 18 weeks, with estimated completion in October 2026. It is being applied topically and assessed against a placebo under double-blind conditions.
Biological: BITR2101
BITR2101 is a monoclonal antibody therapy sponsored by Boston Immune Technologies and Therapeutics, which is being administered through intravenous infusion every three weeks in a Phase 1, first-in-human, dose-escalation study. The drug functions by targeting and inhibiting Tumor Necrosis Factor Receptor 2 (TNFR2), a key signaling molecule that supports lymphoma cell survival, proliferation, and immune evasion in cutaneous T cell lymphoma. The study examines safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in relapsed or refractory non-hodgkin lymphoma patients. It is currently not yet recruiting and is expected to be completed by February 2027.
Drug: DT-7012
DT-7012, a Domain Therapeutics anti-CCR8 monoclonal antibody, is being developed as an intravenous immunotherapy for relapsed or refractory cutaneous T-cell lymphomas, including mycosis fungoides and Sézary syndrome. Sponsored by Assistance Publique–Hôpitaux de Paris, this Phase 1 first-in-human, multicenter, open-label, dose-escalation study is examining safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy. The drug is targeting CCR8-expressing regulatory T cells and is mediating tumor cell depletion through ADCC and ADCP, thereby reshaping the tumor microenvironment. Study completion is expected in August 2028 and is ongoing.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Cutaneous T-cell Lymphoma (CTCL) Pipeline Insight Report
- Which companies/institutions are leading cutaneous T cell lymphoma drug development?
- Which company is leading the cutaneous T cell lymphoma pipeline development activities?
- What is the current cutaneous T cell lymphoma commercial assessment?
- What are the opportunities and challenges present in the cutaneous T cell lymphoma pipeline landscape?
- What is the efficacy and safety profile of cutaneous T cell lymphoma pipeline drugs?
- Which company is conducting major trials for cutaneous T cell lymphoma drugs?
- Which companies/institutions are involved in cutaneous T cell lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in cutaneous T cell lymphoma?
Reasons To Buy This Report
The Cutaneous T-cell Lymphoma (CTCL) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for cutaneous T cell lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into cutaneous T cell lymphoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
